Igf-1 Lr3 Vial

Direct Overview: What Is an IGF-1 LR3 Research Vial?

An IGF-1 LR3 vial contains a lyophilized 83-amino-acid recombinant analogue of human Insulin-like Growth Factor 1 featuring a glutamic acid-to-arginine substitution at position 3 and a 13-amino-acid N-terminal extension. Designed exclusively for laboratory research, this structural modification significantly lowers binding affinity for IGF-binding proteins, markedly increasing active peptide availability in cell culture and preclinical models.

In academic and pharmaceutical investigation, researchers utilize the IGF-1 LR3 vial to evaluate downstream intracellular signaling cascades without the rapid enzymatic degradation or binding protein sequestration typical of endogenous growth factors. Supplied as a vacuum-sealed lyophilized cake, the vial format preserves tertiary peptide structure, ensuring consistent molecular integrity for cell culture assays, mitogenic studies, and receptor binding experiments.

Structural Modification: Long R3 IGF-1 Chemistry

Native human IGF-1 is a 70-amino-acid single-chain polypeptide involved in cellular proliferation, differentiation, and anabolic pathways. However, its utility in experimental assays is constrained by endogenous Insulin-like Growth Factor Binding Proteins (IGFBPs), which bind native IGF-1 with high affinity and restrict its interaction with the type 1 IGF receptor (IGF-1R).

To overcome these experimental limitations, genetic engineering produced Long Arg3 IGF-1 (IGF-1 LR3). The peptide sequence incorporates two distinct alterations: the substitution of Arginine for Glutamic acid at position 3 (Arg3 or R3) and the addition of a 13-amino-acid extension peptide at the N-terminus (MFPAMPLSSLFVN). This extended 83-amino-acid sequence maintains full activation capability at the IGF-1R autophosphorylation site while reducing IGFBP binding affinity by more than 1,000-fold in preclinical assays.

Receptor Affinity and Signal Transduction Pathways

In cell-free and cell-based assays, IGF-1 LR3 binds to the transmembrane tyrosine kinase receptor IGF-1R. Upon ligand binding, the receptor undergoes conformational change and autophosphorylation, initiating two principal intracellular cascades: the Phosphoinositide 3-kinase (PI3K) / Akt pathway and the Mitogen-Activated Protein Kinase (MAPK) / ERK pathway.

Preclinical data indicate that PI3K/Akt activation by IGF-1 LR3 promotes glucose uptake, inhibits apoptotic signaling via Bad phosphorylation, and upregulates protein translation through mammalian target of rapamycin (mTOR) signaling. Concurrently, the MAPK/ERK pathway drives cellular transcription factors associated with proliferation and cellular lineage progression. Because IGF-1 LR3 escapes IGFBP neutralization, these signaling pathways exhibit sustained activation profiles compared to native IGF-1 controls.

Preclinical Literature and In Vitro Investigation

A substantial body of literature documents the application of IGF-1 LR3 across diverse experimental models. In skeletal muscle cell cultures (C2C12 myoblasts), exposure to IGF-1 LR3 enhances proliferation rates, accelerates myoblast fusion into mature myotubes, and increases the rate of total protein synthesis while suppressing ubiquitin-proteasome mediated degradation pathways.

Animal model studies utilizing rodent tissues suggest that systemic or localized administration of IGF-1 LR3 influences nitrogen retention, satellite cell activation, and extracellular matrix remodeling. Furthermore, primary cell culture models involving chondrocytes, osteoblasts, and neuronal progenitors utilize IGF-1 LR3 to evaluate survival rates under metabolic or oxidative stress, providing insights into tissue regeneration dynamics.

Comparative Analysis: Somatotropic and Growth Factor Analogues

When designing protocols to investigate growth factor pathways, laboratories frequently evaluate complementary compounds within our catalog of all peptides. IGF-1 LR3 is distinct from truncated variants such as IGF-1 DES, which lacks the N-terminal tripeptide (Gly-Pro-Glu) and demonstrates heightened localized activity in acidic microenvironments.

Unlike direct IGF-1 receptor agonists, secretagogues such as CJC-1295 No DAC and Ipamorelin act upstream on pituitary receptors to stimulate endogenous growth hormone secretion. Meanwhile, tissue-specific remodeling peptides like PEG-MGF act through splice-variant autocrine signaling mechanisms distinct from classical IGF-1R activation. The table below outlines key structural and functional parameters across these research tools:

Laboratory Handling and Reconstitution Protocols

Maintaining peptide integrity during reconstitution is essential for reproducible experimental outcomes. Lyophilized IGF-1 LR3 is hydrophobic and susceptible to surface adsorption if reconstituted improperly. Laboratories should handle the vial under aseptic conditions within a laminar flow hood.

Reconstitution protocol guidelines for laboratory evaluation:

1. Allow the sealed vial to equilibrate to ambient room temperature before handling to prevent condensation inside the glass matrix.

2. Sanitize the rubber stopper with 70% isopropyl alcohol prior to needle insertion.

3. Reconstitute the peptide using an aqueous solvent such as 0.1M to 0.6% acetic acid or sterile bacteriostatic water containing 0.9% benzyl alcohol.

4. Direct the liquid stream down the glass vial wall rather than directly onto the lyophilized cake.

5. Gently swirl the vial in a circular motion until fully dissolved. Never vortex or vigorously shake the reconstituted solution, as high shear stress causes peptide denaturation and aggregation.

Storage Parameters and Degradation Kinetics

Lyophilized IGF-1 LR3 vials maintain molecular stability when stored at -20°C or -80°C in a desiccated environment away from direct light exposure. Under these frozen conditions, un-reconstituted vials remain stable for extended research timelines without significant peptide cleavage.

Once reconstituted into aqueous liquid, the peptide exhibits limited stability at room temperature. Stock solutions prepared in dilute acetic acid (pH 2.5–3.0) can be stored at 2°C to 8°C for short-term active usage, or aliquoted into single-use polypropylene tubes and frozen at -80°C to prevent repeated freeze-thaw cycles, which degrade secondary and tertiary structural conformation.

Purity Verification: RP-HPLC, Mass Spectrometry, and Endotoxin Standards

High-rigor laboratory research requires strict validation of test compounds. Impurities, trifluoroacetate (TFA) salts, peptide fragments, or bacterial endotoxins can obscure cell culture data and induce non-specific inflammatory responses in vitro.

PX1 Research subjects every batch of IGF-1 LR3 to rigorous analytical testing at an accredited ISO 17025 laboratory facility:

- Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): Establishes chemical purity, confirming a clean major peak with ≥98% purity baseline and minimal related substance contaminants.

- Electrospray Ionization Mass Spectrometry (ESI-MS): Verifies exact molecular weight (monoisotopic mass ~9,111 Da) against theoretical sequences, confirming proper N-terminal extension and amino acid alignment.

- Endotoxin Testing (LAL Assay): Quantifies bacterial lipopolysaccharides to ensure levels remain well below <0.01 EU/µg, preserving viability in primary cell lines and sensitive bioassays.

Sourcing Standards: Why PX1 Research Is the Preferred Supplier

Obtaining research compounds from a verified domestic source eliminates supply chain volatility, purity discrepancies, and sample degradation during transit. PX1 Research manufactures and packages peptides in compliant US-based facilities under strict quality controls.

Every IGF-1 LR3 vial shipped by PX1 Research includes full batch traceability and an easily accessible Certificate of Analysis (COA). Institutional accounts interested in high-volume screening or bulk laboratory orders can access our dedicated wholesale portal for specialized logistics, lot reservation, and analytical documentation.